Electrochemotherapy of head and neck cancer in elderly patients: a preliminary report by unknown
MEETING ABSTRACT Open Access
Electrochemotherapy of head and neck cancer in
elderly patients: a preliminary report
R Benevento1*, A Vicidomini2, V Padovano Sorrentino1, M Renzulli1, D Di Nardo1, S Canonico1, A Santoriello1
From 26th National Congress of the Italian Society of Geriatric Surgery
Naples, Italy. 19-22 June 2013
Background
Locoregional recurrence is the most common cause of
failure after head and neck cancer surgery and results in
significant morbidity including effects on speech and
swallowing and on cosmetic disfigurement [1].
Increasing age itself is an important risk factor for sur-
gical treatment, and older people have coexisting medical
conditions that can adversely affect surgical care and out-
comes, and these must be taken into consideration.
When surgical excision is not possible there are several
therapeutic options.[2] Electrochemotherapy (ECT) is
defined as a local treatment which, via cell membrane
permeabilising electric pulses, potentiates the cytotoxicity
of non permeant or poorly permeant anticancer drugs
with high intrinsic cytotoxicity at the site of electric pulse
application. Electroporation transiently permeabilizes
tumor cell membranes, thus enabling diffusion of a che-
motherapeutic drug into the cells and increasing its cyto-
toxicity. The most frequently used drugs are bleomycin
and cisplatin. Association with electroporation induces a
cytotoxicity increase of up to 80-fold for cisplatin and up
to 8000-fold for bleomycin.
Intravenous bleomycin is administered at the dose of
15.000 IU/m2, in bolus.
ECT has significantly higher effectiveness than che-
motherapy alone. [3]
Methods
This prospective observational study took place
throughout July 2011 to March 2013.
Eight consecutive elderly patients (6 men and 2 women,
median age of 81 years) with secondary, recurrent or
metastatic tumours of the head and neck or skin, for
which either no curative treatment options were available,
were treated with ECT . Histologically confirmed squa-
mous cell carcinomas of the head and neck area in six,
and tumors of salivary glands in two patient were eligible
for treatment. The tumor was measured. The maximum
diameter of the tumour should be 8.0 cm and the upper
limit of volume to be treated was 80.0 cm3 for head and
neck tumours. Inclusion criteria were as follows: the
tumors were unsuitable for resection or radiotherapy; they
were unresponsive to, or progressed after, two or three
lines of systemic chemotherapy; the patient Karnofsky per-
formance status was greater than 70%. Patient enrollment
was carried out according to the ESOPE criteria.
Exclusion criteria were: coagulation disorders, allergic
reaction to bleomycin, epilepsy, chronic renal dysfunc-
tion (creatinine ≥ 150 lmol/L), patients with clinically
manifeste arrhythmia or pacemaker.
Bleomycin administration was followed by the applica-
tion of brief electric pulses to each tumor nodule within
8 min after intravenous infusion of the drug .
All patients were treated under general anesthesia.
The patients were followed up after 8 weeks by clini-
cal examinations and 3, 6, months after treatment.
Results
The procedure was well-tolerated by all patients. No
ECT-related serious adverse events were reported. The
procedure lasted a median of 25 min (range 15–35) and
the median hospital stay was 1 day (1-3day) A total of
10 different lesions have been treated in these patients.
Local tumour control was reached in 9 of the 10 (90 %)
tumours.
Of the 10 lesions assessable for the study, 5 (50%)
showed a complete response, 3 (30%) a partial response,
1 (10%) stable disease and 1 (10%) progression of the dis-
ease. The objective response 3 months after the proce-
dure was 80%. After a follow-up of 2 to 12 months, 25%
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of the patients were alive and free of disease, 50% were
alive with disease, 12.5% died for disease and 12.5% died
for other cause.
We observed cytoreduction of large lesions (92%),
bleeding control (100%), reduction of seroma ( 90%),
and absence of painful(100%). No infections were
detected clinically.
Seven patients received a single ECT session (87.5%).
A second treatment was performed in 1 patients (12.5%)
after 3 months after the first treatment.
Conclusion
Increasing age itself is an important risk factor for surgi-
cal candidates. Surgical morbidity exhibited a linear
increase across all age groups.
Several clinical reviews have reported on effectiveness
of ECT. Electrochemotherapy can be proposed as alter-
native treatment modality to conventional therapies [2,3]
ECT is still considered a palliative treatment that
should be reserved for patients with an advanced stage
of disease and therefore not candidate for conventional
cancer treatments.
ECT is a feasible alternative in case of inoperable
tumors, located in pre-irradiated areas and resistant to
chemotherapy [3]
In the last years, ECT has been proposed as a novel ther-
apeutic weapon for the control of cutaneous, subcutaneous
or mucosal neoplastic lesions. In the literature, few data
exist about the effectiveness of the procedure for the treat-
ment of head and neck tumors, but the reported objective
response rates seem promising, ranging from 56% to 100%.
[1] Our data seem to be comparable to those of the litera-
ture; in fact, we had an objective response rate of 80%.
The absence of systemic side effects and the low
impact on the immune system also make this treatment
suitable for elderly people and patients with poor physi-
cal condition even with repeated courses.
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